Complications and Comorbidities Associated with Antineoplastic Chemotherapy: Rethinking Drug Design and Delivery for Anticancer Therapy

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2024 Jul 19

PMID 39027258

Authors

Xiaoman Mao

Shuang Wu

Dandan Huang

Chong Li

Affiliations

Soon will be listed here.

Abstract

Despite the considerable advancements in chemotherapy as a cornerstone modality in cancer treatment, the prevalence of complications and pre-existing diseases is on the rise among cancer patients along with prolonged survival and aging population. The relationships between these disorders and cancer are intricate, bearing significant influence on the survival and quality of life of individuals with cancer and presenting challenges for the prognosis and outcomes of malignancies. Herein, we review the prevailing complications and comorbidities that often accompany chemotherapy and summarize the lessons to learn from inadequate research and management of this scenario, with an emphasis on possible strategies for reducing potential complications and alleviating comorbidities, as well as an overview of current preclinical cancer models and practical advice for establishing bio-faithful preclinical models in such complex context.

Citing Articles

Anti-Hyperalgesic Effect of Isopulegol Involves GABA and NMDA Receptors in a Paclitaxel-Induced Neuropathic Pain Model.

Martins D, Acha B, Cavalcante M, Pereira S, Viana A, Pinheiro-Neto F Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006070 PMC: 11860001. DOI: 10.3390/ph18020256.

Enhancing the Stability and Anticancer Activity of Asparaginase Through Nanoparticle Immobilization: A Biotechnological Perspective on Nano Chitosan.

Alharthi F, Althagafi H, Jafri I, Oyouni A, Althaqafi M, Al-Hazmi N Polymers (Basel). 2024; 16(23).

PMID: 39684005 PMC: 11644295. DOI: 10.3390/polym16233260.

Cabozantinib-phospholipid complex for enhanced solubility, bioavailability, and reduced toxicity in liver cancer.

Patil J, Bhattacharya S, Saoji S, Dande P Ther Deliv. 2024; 16(1):25-41.

PMID: 39611708 PMC: 11703380. DOI: 10.1080/20415990.2024.2435240.

References

Boyle F, Beatson C, Monk R, Grant S, Kurek J . The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother Pharmacol. 2002; 48(6):429-34. DOI: 10.1007/s00280-001-0382-6. View

Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D . Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13:757-772. PMC: 5927356. DOI: 10.2147/CIA.S158513. View

Mohammed T, Singh M, Tiu J, Kim A . Etiology and management of hypertension in patients with cancer. Cardiooncology. 2021; 7(1):14. PMC: 8022405. DOI: 10.1186/s40959-021-00101-2. View

Yang H, Villani R, Wang H, Simpson M, Roberts M, Tang M . The role of cellular reactive oxygen species in cancer chemotherapy. J Exp Clin Cancer Res. 2018; 37(1):266. PMC: 6211502. DOI: 10.1186/s13046-018-0909-x. View

Lee E . Neurologic Complications of Cancer Therapies. Curr Neurol Neurosci Rep. 2021; 21(12):66. DOI: 10.1007/s11910-021-01151-w. View

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Mackey M, Glisovic S, Leclerc J, Pastore Y, Krajinovic M, Craig M . The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia. Br J Clin Pharmacol. 2020; 87(2):687-693. DOI: 10.1111/bcp.14424. View

Zhou Y, Xia J, Xu S, She T, Zhang Y, Sun Y . Experimental mouse models for translational human cancer research. Front Immunol. 2023; 14:1095388. PMC: 10036357. DOI: 10.3389/fimmu.2023.1095388. View

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

10.

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

11.

Rauf A, Imran M, Ali Khan I, Ur-Rehman M, Gilani S, Mehmood Z . Anticancer potential of quercetin: A comprehensive review. Phytother Res. 2018; 32(11):2109-2130. DOI: 10.1002/ptr.6155. View

12.

Zahedipour F, Butler A, Rizzo M, Sahebkar A . Statins and angiogenesis in non-cardiovascular diseases. Drug Discov Today. 2022; 27(10):103320. DOI: 10.1016/j.drudis.2022.07.005. View

13.

Gao Q, Feng J, Liu W, Wen C, Wu Y, Liao Q . Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. Adv Drug Deliv Rev. 2022; 188:114445. DOI: 10.1016/j.addr.2022.114445. View

14.

Liu H, Luo G, Shang Z . . Acta Pharm Sin B. 2024; 14(1):133-154. PMC: 10792991. DOI: 10.1016/j.apsb.2023.08.033. View

15.

Koelwyn G, Aboumsallem J, Moore K, de Boer R . Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis. J Mol Cell Cardiol. 2021; 163:1-8. PMC: 8816816. DOI: 10.1016/j.yjmcc.2021.09.008. View

16.

Baye E, Naderpoor N, Misso M, Teede H, Moran L, de Courten B . Treatment with high dose salicylates improves cardiometabolic parameters: Meta-analysis of randomized controlled trials. Metabolism. 2017; 71:94-106. DOI: 10.1016/j.metabol.2017.03.006. View

17.

Garcia-Lafuente A, Guillamon E, Villares A, Rostagno M, Martinez J . Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 2009; 58(9):537-52. DOI: 10.1007/s00011-009-0037-3. View

18.

Wu S, Song R, Liu T, Li C . Antifungal therapy: Novel drug delivery strategies driven by new targets. Adv Drug Deliv Rev. 2023; 199:114967. DOI: 10.1016/j.addr.2023.114967. View

19.

Vicentini M, Ballotari P, Rossi P, Venturelli F, Sacchettini C, Greci M . Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: An observational population-based study. Diabetes Res Clin Pract. 2018; 143:398-408. DOI: 10.1016/j.diabres.2018.04.036. View

20.

Rutten I, van Dijk D, Kruitwagen R, Beets-Tan R, Olde Damink S, Van Gorp T . Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016; 7(4):458-66. PMC: 4782251. DOI: 10.1002/jcsm.12107. View